A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas
Tecartus® (brexucabtagene autoleucel)
IJMS | Free Full-Text | CAR-T Cell Therapy: From the Shop to Cancer Therapy
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma
CAR T-Cell Therapies: Trends and Indications - The ASCO Post
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies | Published in healthbook TIMES Oncology Hematology
Tecartus Approved for Some Adults with B-Cell ALL - NCI
Brexucabtagene autoleucel Uses, Side Effects & Warnings
Tecartus (brexucabtagene autoleucel) Cancer Medication - Cancer Health
A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas
Tecartus: Package Insert - Drugs.com
PDF) Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany | Gene Therapy
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies | Published in healthbook TIMES Oncology Hematology
Frequently Asked Questions About Tecartus® (brexucabtagene autoleucel) - CancerConnect
TECARTUS- brexucabtagene autoleucel suspension
SmartPA Criteria Proposal
Frontiers | Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
TECARTUS- brexucabtagene autoleucel suspension
Tecartus (brexucabtagene autoleucel)
Frontiers | Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
PDF) Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
These highlights do not include all the information needed to use TECARTUS safely and effectively. See full prescribing information for TECARTUS. TECARTUS® (brexucabtagene autoleucel) suspension for intravenous infusion Initial U.S. Approval: 2020
Inhaled Corticosteroids
JCM | Free Full-Text | Development of CAR T Cell Therapy in Children—A Comprehensive Overview
CAR T-Cell Indications and Post-Treatment Care
